Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06730308
PHASE2

Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma

Sponsor: Sun Yat-sen University

View on ClinicalTrials.gov

Summary

This study aims to assess the efficacy of methylprednisolone combined with concurrent chemoradiotherapy in treating unresectable or recurrent thymoma.

Official title: A Prospective, Single-arm Phase II Study of Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

45

Start Date

2024-11-20

Completion Date

2028-11-19

Last Updated

2024-12-12

Healthy Volunteers

No

Conditions

Interventions

RADIATION

Radiotherapy

Hypofractionated radiotherapy

DRUG

Concurrent chemotherapy

weekly albumin-bound paclitaxel (50 mg/m²) and cisplatin (25 mg/m²)

DRUG

Methylprednisolone

Methylprednisolone 2mg/kg, qd, concurrent with radiotherapy

Locations (1)

Sun yat-sen University Cancer Center

Guanzhou, Guangdong, China